| [[PAGE:1]] | |
| FREQUENTLY ASKED QUESTIONS | |
| What is the approved starting dose for the authorised product? 80 mg once daily in first-line metastatic EGFR-positive NSCLC within EU label boundaries. | |
| [[PAGE:2]] | |
| MISSED DOSE | |
| Patient-facing answers must use only approved missed-dose guidance and avoid improvised rescue instructions; advise clinician follow-up when uncertain. | |